One Year On: The Bioequivalence Guidelines
Add bookmark
One Year On: The Bioequivalence Guidelines
Add bookmark
Helmut Schuetz of BEBAC Consultancy and Anders Fuglsang of Fuglsang Pharma Consultancy, join Pharma IQ to discuss the impact of the bioequivalence guidelines introduced in summer 2010 on the pharmaceutical industry.
In this debate, we get the views of two key consultants within the field on how well the bioequivalence guidelines have been received, the main changes in the guidelines and how well aware of these the industry has been. They also discuss the problems experienced when it comes to implementing the guidelines and the elements they perceive to be missing which they would like to have seen included. Finally, Schuetz and Fuglsang reflect on how they predict the bioequivalence landscape to change over the next five year.
[inlinead]
